In vitro and in vivo activities of novel cyclic lipopeptides against staphylococcal biofilms

Nina Bionda, Irena Pastar, Stephen C Davis, Predrag Cudic

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr- D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.

Original languageEnglish
Pages (from-to)352-356
Number of pages5
JournalProtein and Peptide Letters
Volume21
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lipopeptides
Biofilms
valylvaline
Microbial Sensitivity Tests
Staphylococcus aureus
Depsipeptides
Anti-Bacterial Agents
Public health
Medical problems
Infection
Biological Products
Bacteria
Swine
Public Health
In Vitro Techniques
Wounds and Injuries
Growth
Pharmaceutical Preparations

Keywords

  • Antibiotics
  • Biofilm
  • Cyclic lipopeptides
  • Eradication
  • Fusaricidins/LI-Fs
  • MRSA
  • Porcine model
  • Wound

ASJC Scopus subject areas

  • Biochemistry
  • Structural Biology

Cite this

In vitro and in vivo activities of novel cyclic lipopeptides against staphylococcal biofilms. / Bionda, Nina; Pastar, Irena; Davis, Stephen C; Cudic, Predrag.

In: Protein and Peptide Letters, Vol. 21, No. 4, 01.01.2014, p. 352-356.

Research output: Contribution to journalArticle

@article{efb6183976a94bd480b75c715ea37106,
title = "In vitro and in vivo activities of novel cyclic lipopeptides against staphylococcal biofilms",
abstract = "A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr- D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.",
keywords = "Antibiotics, Biofilm, Cyclic lipopeptides, Eradication, Fusaricidins/LI-Fs, MRSA, Porcine model, Wound",
author = "Nina Bionda and Irena Pastar and Davis, {Stephen C} and Predrag Cudic",
year = "2014",
month = "1",
day = "1",
doi = "10.2174/09298665113206660101",
language = "English",
volume = "21",
pages = "352--356",
journal = "Protein and Peptide Letters",
issn = "0929-8665",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - In vitro and in vivo activities of novel cyclic lipopeptides against staphylococcal biofilms

AU - Bionda, Nina

AU - Pastar, Irena

AU - Davis, Stephen C

AU - Cudic, Predrag

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr- D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.

AB - A worldwide public health problem has resulted from the alarming spread of multi-drug resistant bacteria combined with the frequent occurrence of biofilm-type infections, creating a growing need for new therapies. In this study, we have demonstrated that novel cyclic lipopeptides, such as 1, cyclo-[D-Ala-(12-guanidinododecanoyl)Thr-D-Val-Val-DaThr- D-Asn], and 2, cyclo-[D-Ala-(12-guanidinododecanoyl)Dap-D-Val-Val-D-aThr-D-Asn], derived from the fusaricidin/ LI-F natural products efficiently inhibit the growth of Staphylococcus aureus biofilm in vitro at their minimum inhibitory concentrations (MICs). Complete S. aureus biofilm eradication was observed at 3 x MIC for 1 and 4 x MIC for 2. Promising in vivo activity was demonstrated by the ability of depsipeptide 1 to reduce the proliferation of methicillinresistant S. aureus US300 in a porcine wound model. Due to their unique structure and potent antibacterial and antibiofilm activities, cyclic lipopeptides that belong to the fusaricidin/LI-F family of antibiotics represent particularly attractive lead structures for the development of new antibacterial agents capable of treating complicated biofilm-associated infections.

KW - Antibiotics

KW - Biofilm

KW - Cyclic lipopeptides

KW - Eradication

KW - Fusaricidins/LI-Fs

KW - MRSA

KW - Porcine model

KW - Wound

UR - http://www.scopus.com/inward/record.url?scp=84896326517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896326517&partnerID=8YFLogxK

U2 - 10.2174/09298665113206660101

DO - 10.2174/09298665113206660101

M3 - Article

C2 - 24164269

AN - SCOPUS:84896326517

VL - 21

SP - 352

EP - 356

JO - Protein and Peptide Letters

JF - Protein and Peptide Letters

SN - 0929-8665

IS - 4

ER -